+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.



          The use of a combination inhaler containing budesonide and formoterol (BUD/FOR) to both maintenance and quick relief therapy has been recommended as an improved method of using inhaled corticosteroid/long-acting β agonist therapy. The aim of this study was to investigate the acute effects of BUD/FOR and testing the availability of BUD/FOR for early reversibility test in patients with airway obstruction.

          Patients and methods

          The study was conducted on patients who were admitted to the Department of Pulmonary Medicine, Samsun Medical Park Hospital, Samsun, Turkey.


          A total of 44 patients were included in the study. The mean age of patients was 48.5±17.3 (range 10–75) years and the male-to-female ratio was 36:8. The pre-bronchodilator pulmonary function test results are as follows: the mean forced vital capacity, 3,025±1,162 mL (76.3%±23.2%); mean forced expiratory volume in 1 second (FEV 1), 1,898±725 mL (59.2%±19.1%); mean FEV 1/forced vital capacity, 62.8±6.3% (range 42%–70%); mean peak expiratory flow, 3,859±1,779 mL (48.0%±19.7%); and forced expiratory flow 25%–75%, 1,295±486 mL (35.8%±12.3%). The reversibility was positive in 26 (59.1%) patients. The absolute change and percentage of change in FEV 1 were 318±228 mL and 17.7%±11.9%, respectively. The patients were divided into two groups according to reversibility (reversible and irreversible) and both groups were compared with changes according to spirometric results. FEV 1 values were statistically different between the two groups.


          The fixed combination of BUD/FOR has rapid bronchodilator effect, and they can be used for early reversibility test.

          Related collections

          Most cited references 7

          • Record: found
          • Abstract: found
          • Article: not found

          Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial.

          The Single combination budesonide-formoterol inhaler Maintenance And Reliever Therapy (SMART) regimen reduces severe asthma exacerbations in patients, but whether the high doses of corticosteroid and β agonist increase the risk of adverse effects with both short-term and cumulative exposure is not certain. Our aim was to investigate whether the SMART regimen would reduce the risk of overuse of β agonist, reduce the likelihood of patients to seek medical review when such episodes occurred, and if any reduction in severe asthma exacerbations would be at the cost of a higher burden of systemic corticosteroid.
            • Record: found
            • Abstract: found
            • Article: not found

            Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.

            Traditionally inhaled treatment for asthma has used separate preventer and reliever therapies. The combination of formoterol and budesonide in one inhaler has made possible a single inhaler for both prevention and relief of symptoms (single inhaler therapy or SiT).
              • Record: found
              • Abstract: found
              • Article: not found

              Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma.

              There are significant health disparities between Māori and non-Māori with asthma, a pattern seen between other ethnic populations. This study investigates outcomes for Māori in a randomized controlled trial (RCT) of combination budesonide/formoterol inhaler therapy in asthma.

                Author and article information

                Drug Des Devel Ther
                Drug Des Devel Ther
                Drug Design, Development and Therapy
                Drug Design, Development and Therapy
                Dove Medical Press
                21 September 2015
                : 9
                : 5287-5290
                [1 ]Department of Pulmonary Medicine, Faculty of Medicine, Bahcesehir University, Istanbul, Turkey
                [2 ]Department of Pulmonary Medicine, Samsun Medical Park Hospital, Samsun, Turkey
                Author notes
                Correspondence: Sevket Ozkaya, Department of Pulmonary Medicine, Faculty of Medicine, Bahcesehir University, Çırağan Caddesi Osmanpaşa Mektebi Sokak No: 4, Beşiktaş, Istanbul 634353, Turkey, Tel +90 532 474 1309, Email ozkayasevket@ 123456yahoo.com
                © 2015 Bayiz et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

                The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

                Original Research


                Comment on this article